CASI Pharmeceuticals

Drug Candidates

CASI’s Pipeline

CASI’s product pipeline offers promising and unique opportunities for development and commercialization for the following reasons:

Multiple Mechanisms of Action
Diseases such as cancer employ multiple strategies to survive involving various cellular signaling pathways that promote their transformation and growth. Cancer cells can rapidly evade drugs that are highly specific for a target within one of these pathways through the development of resistance mechanisms. If more than one of these redundant signaling pathways can be interrupted at once, then the chance for resistance to develop is greatly reduced. ENMD-2076 acts by attacking cancer cells through multiple pathways that promote the formation and replication of tumor cells, while also interrupting the formation of blood vessels that nourish and sustain tumor growth. CASI has pursued oncology indications that could provide proof-of-concept data to support the design of pivotal trials.

While the Company’s clinical efforts continue to focus on oncology, CASI believes that other diseases where angiogenesis plays a role in pathology represent future opportunities.

Intellectual Property Position
All CASI’s drug candidates are backed by strong international intellectual property rights, including issued or pending composition, method and use patents.

About Us

A leading US-headquartered, NASDAQ-listed, biopharmaceutical company targeting the global market, with a focus on China.

Learn More

In the News

EntreMed leverages best of China and the West and seeks to expand pipeline.

Read Article →


Phase II Study of Oral ENMD-2076 Administered to Patients (pts) With Advanced Soft Tissue Sarcoma

Download →


Phase II Study of Oral ENMD-2076 Administered to Patients with Ovarian Clear Cell Carcinoma

Download →